JAK2 and cyclic hematopoiesis: CH is defined as the presence of a somatic mutation associated with hematological malignancies, such as ASXL1, DNMT3A, JAK2, TET2, and TP53, without morphologic or clinical evidence of a hematological neoplasm [4,5].